Lyssikatos Joseph P
SEC CIK 1967150 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | CSO, Dir | 18.8K | — | $11.75M | 49 | 2023-02-23 | 2026-02-12 |
Most active insiders at ELVN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 10% | — | $51.68M |
| 2 | Derynck Mika K | Dir | — | $9.56M |
| 3 | Collins Helen Louise | Chief MEDICAL Off | — | $5.39M |
| 4 | Lyssikatos Joseph P | CSO | — | $4.88M |
| 5 | Patel Anish | COO | — | $1.74M |
| 6 | Hohl Benjamin | CFO | — | $1.60M |
| 7 | Kunkel Lori Anne | Dir | — | $850.3K |
| 8 | Kintz Samuel | Pres AND CEO, Dir | — | $613.6K |
| 9 | Heyman Richard A. | Dir | — | $413.4K |
Transactions 49
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-17 | 2026-02-12 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | A - Grant | $0.00 | +18.8K | 18.8K | New | $0 |
| I | 2026-02-10 | 2026-02-06 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $29.04 | -5,000 | 740.2K | -0.7% | -$145.2K |
| MI | 2026-01-22 | 2026-01-20 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $26.75 | -20.0K | 759.7K | -3% | -$535.1K |
| MI | 2026-01-12 | 2026-01-08+ | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $26.23 | -132.5K | 765.2K | -15% | -$3.48M |
| I | 2025-12-23 | 2025-12-19 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $16.84 | -5,000 | 897.7K | -0.6% | -$84.2K |
| MI | 2025-11-21 | 2025-11-19 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $22.33 | -12.5K | 902.7K | -1% | -$279.1K |
| I | 2025-10-22 | 2025-10-20 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $22.08 | -12.5K | 915.2K | -1% | -$276.0K |
| I | 2025-09-30 | 2025-09-26 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $20.25 | -4,000 | 927.7K | -0.4% | -$81.0K |
| I | 2025-09-25 | 2025-09-23 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $20.03 | -1,500 | 931.7K | -0.2% | -$30.0K |
| MI | 2025-09-23 | 2025-09-19 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $19.39 | -7,000 | 933.2K | -0.7% | -$135.7K |
| MI | 2025-08-21 | 2025-08-19+ | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $19.85 | -12.5K | 940.2K | -1% | -$248.2K |
| MI | 2025-07-23 | 2025-07-21 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $22.29 | -12.5K | 952.7K | -1% | -$278.6K |
| I | 2025-06-24 | 2025-06-20 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $21.40 | -12.5K | 965.2K | -1% | -$267.5K |
| I | 2025-06-05 | 2025-06-03 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $20.03 | -7,500 | 977.7K | -0.8% | -$150.2K |
| I | 2025-05-21 | 2025-05-19 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $16.31 | -5,000 | 985.2K | -0.5% | -$81.5K |
| MI | 2025-05-05 | 2025-05-01+ | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $20.05 | -7,500 | 992.7K | -0.7% | -$150.4K |
| MI | 2025-04-23 | 2025-04-21 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $16.08 | -5,000 | 998.0K | -0.5% | -$80.4K |
| I | 2025-03-21 | 2025-03-19 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $20.61 | -12.5K | 1.00M | -1% | -$257.6K |
| I | 2024-10-22 | 2024-10-18 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $30.00 | -847 | 1.02M | -0.1% | -$25.4K |
| MI | 2024-10-10 | 2024-10-08+ | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $28.11 | -51.1K | 1.05M | -5% | -$1.44M |
| MI | 2024-10-08 | 2024-10-04+ | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $27.54 | -10.2K | 1.07M | -0.9% | -$281.7K |
| I | 2024-10-03 | 2024-10-01 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $27.54 | -527 | 1.08M | -0.0% | -$14.5K |
| MI | 2024-09-03 | 2024-08-29 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $22.48 | -12.0K | 1.08M | -1% | -$269.8K |
| I | 2024-08-02 | 2024-07-31 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $27.56 | -3,099 | 1.09M | -0.3% | -$85.4K |
| MI | 2024-07-31 | 2024-07-29 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $26.70 | -12.0K | 1.09M | -1% | -$320.4K |
| I | 2024-07-03 | 2024-07-01 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO | S - Sale | $22.89 | -12.0K | 1.11M | -1% | -$274.7K |
| DM | 2024-05-31 | 2024-05-29 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | S - Sale+OE | $21.73 | -12.0K | 0 | -100% | -$260.8K |
| D | 2024-05-31 | 2024-05-29 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | M - OptEx | $1.12 | +12.0K | 12.0K | New | +$13.4K |
| D | 2024-05-01 | 2024-04-29 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | M - OptEx | $1.12 | +12.0K | 12.0K | New | +$13.4K |
| DM | 2024-05-01 | 2024-04-29 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | S - Sale+OE | $17.91 | -12.0K | 1,013 | -92% | -$214.9K |
| D | 2024-04-15 | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | S - Sale+OE | $25.04 | -30.0K | 0 | -100% | -$751.2K |
| D | 2024-04-15 | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | M - OptEx | $1.12 | +30.0K | 30.0K | New | +$33.6K |
| DM | 2024-04-03 | 2024-04-01 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | S - Sale+OE | $18.59 | -12.0K | 9,648 | -55% | -$223.1K |
| D | 2024-04-03 | 2024-04-01 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | M - OptEx | $1.12 | +12.0K | 12.0K | New | +$13.4K |
| DM | 2024-03-04 | 2024-02-29 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | S - Sale+OE | $16.42 | -12.0K | 0 | -100% | -$197.0K |
| D | 2024-03-04 | 2024-02-29 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | M - OptEx | $1.12 | +12.0K | 12.0K | New | +$13.4K |
| D | 2024-01-31 | 2024-01-29 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | S - Sale+OE | $15.85 | -12.0K | 0 | -100% | -$190.2K |
| D | 2024-01-31 | 2024-01-29 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | M - OptEx | $1.12 | +12.0K | 12.0K | New | +$13.4K |
| D | 2024-01-03 | 2023-12-29 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | M - OptEx | $1.12 | +12.0K | 12.0K | New | +$13.4K |
| DM | 2024-01-03 | 2023-12-29 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | S - Sale+OE | $14.28 | -12.0K | 0 | -100% | -$171.4K |
| DM | 2023-12-26 | 2023-12-21+ | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | S - Sale+OE | $13.07 | -6,566 | 0 | -100% | -$85.8K |
| DM | 2023-12-26 | 2023-12-21+ | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | M - OptEx | $1.12 | +6,566 | 20 | New | +$7,354 |
| DM | 2023-12-21 | 2023-12-19+ | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | M - OptEx | $1.12 | +8,888 | 8,688 | New | +$9,955 |
| DM | 2023-12-21 | 2023-12-19+ | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | S - Sale+OE | $13.01 | -8,888 | 0 | -100% | -$115.6K |
| D | 2023-11-06 | 2023-11-03 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | S - Sale+OE | $13.08 | -8,546 | 0 | -100% | -$111.8K |
| D | 2023-11-06 | 2023-11-03 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | M - OptEx | $1.12 | +8,546 | 8,546 | New | +$9,572 |
| D | 2023-10-03 | 2023-09-29 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | S - Sale+OE | $13.62 | -12.0K | 0 | -100% | -$163.4K |
| D | 2023-10-03 | 2023-09-29 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | M - OptEx | $1.12 | +12.0K | 12.0K | New | +$13.4K |
| DI | 2023-02-27 | 2023-02-23 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CSO, Dir | A - Grant | — | +1.12M | 1.12M | New | — |
Purchase Sale Sale after option exercise All abbreviations